Table 1.
Treatment characteristics
| Patients | Percent | |
|---|---|---|
| Chemotherapy combinations | ||
| Docetaxel + Cisplatin (±5FU) | 15 | 23.8 % |
| FOLFOX | 12 | 19 % |
| FEC | 10 | 15.8 % |
| Paclitaxel + Carboplatin | 7 | 11.1 % |
| Capecitabine | 5 | 8 % |
| FUFA | 2 | 3.1 % |
| Others | 12 | 19.2 % |
| Radiotherapy areas | ||
| Bony areas | 15 | 23.8 % |
| Pelvic region | 10 | 15.8 % |
| Thoracic region | 7 | 11.1 % |
| Upper abdomen | 4 | 6.3 % |
| Brain | 1 | 1.5 % |
Abbreviations: 5FU 5-Fluorouracil, FOLFOX, 5-Fluorouracil, Folinic Acid, Oxaliplatin, FEC 5-Fluorouracil, Epirubicin, Cyclophosphamide, FUFA 5-Fluorouracil, Folinic Acid